Elucidating IL-6/STAT3-mediated Phenotypic Changes in Head and Neck Cancer Stem Cells

阐明头颈癌干细胞中 IL-6/STAT3 介导的表型变化

基本信息

项目摘要

ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is a frequent and deadly malignancy. Despite significant advances in the understanding of the pathobiology of HNSCC, the substantial patient morbidity associated with treatment and the high frequency of tumor recurrence/metastasis result in an unacceptably low patient survival and poor quality of life. The cancer stem cell (CSC) hypothesis attempts to explain the observed heterogeneity of cancer cells within a tumor, with many malignant features of a cancer cell deriving from a shift towards stem- like features. CSCs function as drivers of tumor initiation, therapeutic evasion, and recurrence in HNSCC. Platinum-based agents such as Cisplatin have been shown to enhance the CSC fraction and self-renewal, as determined by Bmi-1 expression. Head and neck CSCs rely on cellular crosstalk within the perivascular niche, particularly on endothelial cell-secreted IL-6. Our preliminary data showed that IL-6/STAT3 inhibition prevents Cisplatin-induced CSC self-renewal. But the mechanism through which inhibition of IL-6 signaling asserts this function and its implications on therapeutic resistance and tumor recurrence remain unclear. The long-term objective of this project is to study molecular mechanisms underlying the acquisition and maintenance of the stem-like cancer cell phenotype. The overall hypothesis of this work is that therapeutic blockade of the IL- 6/STAT3 pathway suppresses the Bmi-1-mediated CSC self-renewal and inhibits HNSCC recurrence. To test this hypothesis, we propose the following specific aims: 1) to elucidate mechanisms underlying IL-6/STAT3- mediated phenotypic changes in the cancer cell population, 2) to describe the real-time effect of IL-6/STAT3 inhibition and Cisplatin therapy on CSC proliferation patterns, and 3) to determine the effect of inhibiting CSC self-renewal on resistance to conventional Cisplatin therapy and recurrence in HNSCC. To accomplish these aims, both genetic and pharmacologic approaches will be used in CSC assays in vitro and in vivo to test the hypothesis that the CSC phenotype is regulated by Bmi-1 via IL-6/STAT3 signaling. We will investigate the real- time phenotypic changes within the CSC population using a CRISPR/Cas9 reporter system to test the hypothesis that IL-6/STAT3 inhibition promotes asymmetric cell division of CSC by decreasing their self-renewal. Cisplatin- resistant cell lines and patient-derived xenograft mouse models will be used to test the hypothesis that inhibiting IL-6/STAT3 signaling will overcome evasive resistance to Cisplatin and prevent tumor recurrence. Elucidating crucial mechanisms that define the fate of head and neck cancer stem cells will inform mechanism-based therapies that have the potential to enhance the survival and quality of life of patients with head and neck cancer.
抽象的 头颈鳞状细胞癌(HNSCC)是一种常见且致命的恶性肿瘤。尽管显着 对 HNSCC 病理学理解的进展,与 HNSCC 相关的大量患者发病率 治疗和肿瘤复发/转移的高频率导致患者生存率低得令人无法接受 和生活质量差。癌症干细胞(CSC)假说试图解释观察到的异质性 肿瘤内癌细胞的许多恶性特征源于干细胞的转变 喜欢特征。 CSC 是 HNSCC 肿瘤发生、治疗逃避和复发的驱动因素。 铂基药物(例如顺铂)已被证明可以增强 CSC 分数和自我更新,因为 由 Bmi-1 表达确定。头颈 CSC 依赖于血管周围微环境内的细胞串扰, 特别是内皮细胞分泌的 IL-6。我们的初步数据表明,IL-6/STAT3 抑制可预防 顺铂诱导 CSC 自我更新。但抑制 IL-6 信号传导的机制证实了这一点 其功能及其对治疗耐药和肿瘤复发的影响仍不清楚。长期来看 该项目的目标是研究获得和维持的分子机制 干细胞样癌细胞表型。这项工作的总体假设是,治疗性阻断 IL- 6/STAT3 通路抑制 Bmi-1 介导的 CSC 自我更新并抑制 HNSCC 复发。到 为了检验这一假设,我们提出以下具体目标:1)阐明IL-6/STAT3-的潜在机制 介导的癌细胞群表型变化,2) 描述 IL-6/STAT3 的实时效果 抑制和顺铂治疗对CSC增殖模式的影响,以及3)确定抑制CSC的效果 自我更新对传统顺铂治疗的耐药性和 HNSCC 的复发。为了完成这些 的目标,遗传和药理学方法将用于 CSC 体外和体内测定,以测试 假设 CSC 表型由 Bmi-1 通过 IL-6/STAT3 信号传导调节。我们将调查真实情况—— 使用 CRISPR/Cas9 报告系统检测 CSC 群体内表型变化的时间来检验假设 IL-6/STAT3 抑制通过减少 CSC 的自我更新来促进 CSC 的不对称细胞分裂。顺铂- 耐药细胞系和患者来源的异种移植小鼠模型将用于检验抑制 IL-6/STAT3 信号传导将克服对顺铂的逃避耐药性并防止肿瘤复发。阐明 定义头颈癌干细胞命运的关键机制将为基于机制的研究提供信息 有潜力提高头颈癌患者的生存率和生活质量的疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexandra Eileen Herzog其他文献

Alexandra Eileen Herzog的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexandra Eileen Herzog', 18)}}的其他基金

Elucidating IL-6/STAT3-mediated Phenotypic Changes in Head and Neck Cancer Stem Cells
阐明头颈癌干细胞中 IL-6/STAT3 介导的表型变化
  • 批准号:
    10228546
  • 财政年份:
    2019
  • 资助金额:
    $ 5.15万
  • 项目类别:
Elucidating IL-6/STAT3-mediated Phenotypic Changes in Head and Neck Cancer Stem Cells
阐明头颈癌干细胞中 IL-6/STAT3 介导的表型变化
  • 批准号:
    10458568
  • 财政年份:
    2019
  • 资助金额:
    $ 5.15万
  • 项目类别:

相似海外基金

A methodology to connect functionalized gonadal constructs to a chick embryo through mechanically induced blood vessels from an egg
一种通过鸡蛋机械诱导血管将功能化性腺结构连接到鸡胚胎的方法
  • 批准号:
    24K15741
  • 财政年份:
    2024
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
All-in-One Smart Artificial Blood Vessels
一体化智能人造血管
  • 批准号:
    EP/X027171/2
  • 财政年份:
    2024
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Fellowship
Development of nextgeneration cellular artificial blood vessels for coronary artery bypass surgery using bio-3D printer
使用生物 3D 打印机开发用于冠状动脉搭桥手术的下一代细胞人造血管
  • 批准号:
    23H02991
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Tissue engineered blood vessels
组织工程血管
  • 批准号:
    2891099
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Studentship
ealization of navigation surgery by automatic recognition of stomach and surrounding blood vessels using artificial intelligence
利用人工智能自动识别胃及周围血管,实现导航手术
  • 批准号:
    23K07176
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Realtime observation and optical control of living microbial probes in blood vessels
血管内活微生物探针的实时观察和光学控制
  • 批准号:
    23H00551
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Creation of a technique for visualization of stress concentration in blood and blood vessels by combined measurement of photoelasticity and ultrasonic Doppler velocimetry
通过光弹性和超声多普勒测速的组合测量,创建了一种可视化血管中应力集中的技术
  • 批准号:
    23H01343
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Shear stress-activated synthetic cells for targeted drug release in stenotic blood vessels
剪切应力激活合成细胞用于狭窄血管中的靶向药物释放
  • 批准号:
    10749217
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
Creation of 3D tissue culture system integrated with blood vessels and autonomic nerves
打造血管与植物神经融合的3D组织培养系统
  • 批准号:
    23H01827
  • 财政年份:
    2023
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Biological function of osteoporotic drugs on bone-specific blood vessels and perivascular cells
骨质疏松药物对骨特异性血管和血管周围细胞的生物学功能
  • 批准号:
    22K21006
  • 财政年份:
    2022
  • 资助金额:
    $ 5.15万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了